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ABSTRACT
Objective: Hospital-acquired pneumonia remains the
most lethal and expensive nosocomial infection
worldwide. Optimal therapy remains controversial. We
aimed to compare mortality and clinical response
outcomes in patients treated with either linezolid or
vancomycin.
Design: Systematic review and meta-analysis.
Data sources: PubMed, EMBASE, Cochrane Library,
American College of Physicians Journal Club,
Evidence-based Medicine BMJ and abstracts from
infectious diseases and critical care meetings were
searched through April 2013.
Eligibility criteria for selecting studies: All
randomised clinical trials comparing linezolid to
vancomycin for hospital-acquired pneumonia.
Data extraction: Preferred reporting items for
systematic reviews and meta-analyses guidelines were
followed. One author extracted the data and two
authors rechecked and verified all data.
Results: Nine randomised trials with a total of 4026
patients were included. The adjusted absolute mortality
risk difference (RD) between linezolid and vancomycin
was 0.01% (95% CI −2.1% to 2.1%; p=0.992;
I2=13.5%. The adjusted absolute clinical response
difference was 0.9% (95% CI −1.2% to 3.1%;
p=0.409; I2=0%. The risk of both microbiological
(RD=5.6%, 95% CI −2.2% to 13.3%; p=0.159; I2=0%)
and methicillin-resistant Staphylococcus aureus
(RD=6.4%, 95% CI −4.1% to 16.9%; p=0.230; I2=0%)
eradication were not different between linezolid and
vancomycin. Gastrointestinal side effects were more
frequent with linezolid (RD=0.8% (95% CI 0% to
1.5%; p=0.05), but no differences were found with
renal failure, thrombocytopenia and drug
discontinuation due to adverse events. Our sample size
provided 99.9% statistical power to detect differences
between drugs regarding clinical response and
mortality.
Conclusions: Linezolid and vancomycin have
similar efficacy and safety profiles. The high
statistical power and the near-zero efficacy difference
between both antibiotics demonstrates that no drug is
superior for the treatment of hospital-acquired
pneumonia.
INTRODUCTION
Hospital-acquired pneumonia (HAP) remains
among the most frequent type of infection
acquired in intensive care unit settings1 2 and
is associated with substantial mortality, ranging
from 15 to 57%.3 Gram-positive organisms,
mainly Staphylococcus aureus, cause approxi-
mately one-third of these pneumonias.3 4
The optimal antibiotic therapy for the treat-
ment of HAP caused by Gram-positive organ-
isms is controversial.5–7 Two systematic reviews
and meta-analyses have been performed com-
paring linezolid to glycopeptides for the treat-
ment of HAP.8 9 The conclusions of both
meta-analyses were similar and consistent: clin-
ical cure and survival were equivalent for line-
zolid, vancomycin and teicoplanin. However,
new randomised trials have been published
since these meta-analyses, the most recent of
which concluded that linezolid is superior to
vancomycin.10 This has reawakened contro-
versy regarding the optimal therapy for
Gram-positive HAP.
There are important public health reasons
to resolve the controversy regarding the
optimal treatment for Gram-positive HAP. A
perceived difference in clinical efﬁcacy is likely
ARTICLE SUMMARY
Strengths and limitations of this study
▪ Linezolid and vancomycin have similar efficacy
and safety profiles.
▪ The near-zero efficacy difference between both
antibiotics demonstrates that no drug is superior
for the treatment of hospital-acquired pneumonia.
▪ Our results remained consistent across different
patient populations and study designs for both
clinical response and mortality outcomes.
▪ Randomised controlled trials set selective inclu-
sion criteria that can limit their generalisability to
unselected populations.
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to drive increased usage of one agent versus the other with
consequent risk of unintended consequences. In the case
of linezolid, these include increased risk of outbreaks of
linezolid resistant organisms, higher total drug costs and
adverse drug events such as serotonin syndrome in
patients with interacting medications and cytopenias in
patients treated with prolonged courses.11 In the case of
vancomycin, these include increased risk of clinical failure
if the drug is underdosed, increased risk of nephrotoxicity
if the drug is overdosed and central venous catheter com-
plications such as bloodstream infections and thrombo-
embolic disease.12
In light of the renewed controversy and public health
signiﬁcance regarding optimal treatment for Gram-posi-
tive HAP, we present the largest systematic review and
meta-analysis on the efﬁcacy and safety of linezolid versus
vancomycin incorporating these new studies. Our study
has long-term implications for two reasons: (1) the cumu-
lative number of patients and events now available for ana-
lysis (4026) allow close to 100% statistical power to detect a
difference in mortality outcome between these two treat-
ments, that is, it is unlikely that any future trial would add
clinically meaningful information, and (2) the manufac-
turer (Pﬁzer) does not plan to perform any more rando-
mised trials with either drug.13
MATERIAL AND METHODS
Literature search
A systematic literature search was independently per-
formed through April 2013 in MEDLINE/PubMed,
EMBASE and Cochrane Library by a professional librar-
ian (Dr Cynthia Schmidt) and by one of the authors
(AK). Any disagreement was resolved by a consensus. We
also searched abstracts published in the same time
period from the following meetings: Society of Critical
Care Medicine, Infectious Diseases Society of America,
the Interscience Conference on Antimicrobial Agents
and Chemotherapy, Chest, and American Thoracic
Society. Relevant Internet sites such as the Food and
Drug Administration reports and trial results repositories
(http://www.clinicalstudyresults.org and http://www.
clinicaltrialresults.org) were also searched. The keywords
used were: linezolid, oxazolidinone, vancomycin, glyco-
peptide, Staphylococcus, Gram-positive, infections, rando-
mised, prospective, lungs, respiratory, hospital-acquired,
ventilator-associated and nosocomial pneumonia. No
language restrictions were used. This study was
exempted from Institutional Review Board approval.
Study selection
Randomised clinical trials that compared linezolid to
vancomycin for the treatment of HAP were included in
our analysis. Trials that did not use vancomycin as the
comparator were excluded. Also excluded were articles
not containing original research (eg, narrative reviews,
editorials and case reports).
Data extraction
The following variables were abstracted and collected in
a standardised form: authors, publication year, study
design, gender, mean age, sample size, site of infection,
microorganism species and susceptibility, clinical
response, microbiological eradication, mortality and
adverse events. For studies that included multiple sites of
infection, we extracted data only from the patient popu-
lation with HAP. Any disagreement was resolved by
further review of the study and consensus among
authors.
Efficacy and safety outcome definitions
Primary efﬁcacy outcomes (1) mortality was deﬁned as
an all-cause 28-day mortality reported by each study and
(2) clinical response was deﬁned at the test of cure
evaluation (TOC) or at the follow-up visit (FUV) for the
clinically evaluable population. If TOC data were not
available, then clinical response at the last study
follow-up was used. Secondary efﬁcacy outcomes: (1)
microbiological eradication was deﬁned as documented
eradication of all Gram-positive organisms at TOC for
the microbiologically evaluable population. If TOC data
were not available, then microbiological eradication at
the last study follow-up was used. (2) Methicillin-resistant
Staphylococcus aureus (MRSA) eradication was deﬁned as
documented eradication of MRSA within the microbio-
logically evaluable population. (3) Safety: gastrointestinal
events included nausea, vomiting, diarrhoea, hepatitis
and pancreatitis; renal failure and thrombocytopenia
were deﬁned as reported by the authors of each paper.
Study drug discontinuation was deﬁned as the perman-
ent discontinuation of either linezolid or vancomycin
due to an adverse event.
Statistical analysis
All results were reported with the random-effects model.
The Q statistic method was used to assess statistical het-
erogeneity and the I-squared (I2) statistic was used to
evaluate the inconsistency between trials.14 15 All abso-
lute risk difference estimates were pooled by using the
DerSimonian and Laird methodology.16 We choose the
risk difference over the risk ratio in order to better
describe the direct clinical effects of our ﬁndings. The
quality of each trial was evaluated by the Jadad criteria.
Preferred reporting items for systematic reviews and
meta-analyses guidelines17 for reporting meta-analysis
were followed. All analyses were adjusted for the study
design to account for potential ascertainment bias. The
software used was Comprehensive Meta-Analysis V.2.0
(Biostat, Englewood, New Jersey, USA). Egger regression
and Begg and Mazumdar18 methods were used to evalu-
ate publication bias. Statistical power calculations were
performed based on the comparison of two independ-
ent proportions by χ2 testing using the software Power
and Precision V.4.0 (Englewood, New Jersey, USA). The
two-group test of proportions was used to test the null
hypothesis that the proportion of cases meeting the
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primary outcome was identical in the two groups.
Hierarchy was not accounted for because the τ was 0,
which indicated that the power based on either
ﬁxed-effect or random-effects modelling produced
exactly the same results.15
RESULTS
A total of nine trials met the inclusion criteria10 19–26
(ﬁgure 1) with a total sample size of 4026 patients. Study
characteristics are presented in table 1, and quality of evi-
dence is presented in the online supplementary data.
EFFICACY ANALYSES
Mortality
The absolute risk difference (RD) between linezolid and
vancomycin for 28-day all-cause mortality based on the
intention-to-treat population (N=4026) was 0.0001 (95%
CI −0.021 to 0.021; p=0.992; I2=13.5%; ﬁgure 2).
Clinical response
The absolute RD between linezolid and vancomycin for
clinical response based on the intention-to-treat popula-
tion (N=3637) was 0.009 (95% CI −0.012 to 0.031;
p=0.409; I2=0%; ﬁgure 3A). The RD between linezolid
and vancomycin for clinical response based on the clin-
ically evaluable and per protocol population (N=1161)
was 0.037 (95% CI −0.019 to 0.092; p=0.192; I2=0%;
ﬁgure 3B). The clinical response on the per protocol
population with MRSA infection only (N=507) showed
an RD=0.077 (95%CI −0.008 to 0.162; p=0.076).
Microbiological eradication
The absolute RD between linezolid and vancomycin for
microbiological eradication based on the microbiologically
evaluable and per protocol population (N=600) was 0.056
(95% CI −0.022 to 0.133; p=0.159; I2=0%; ﬁgure 4A).
MRSA eradication
The absolute RD between linezolid and vancomycin for
MRSA eradication based on the microbiologically evalu-
able and per protocol population (N=416) was 0.064
(95% CI −0.041 to 0.169; p=0.230; I2=0%; ﬁgure 4B).
SAFETY ANALYSES
Gastrointestinal events
The absolute RD between linezolid and vancomycin for
gastrointestinal events based on the intention-to-treat
population (N=3421) was 0.008 (95% CI −0.000 to
0.015; p=0.050; I2=78%; ﬁgure 5A).
Thrombocytopenia
The absolute RD between linezolid and vancomycin for
thrombocytopenia based on the intention-to-treat popu-
lation (N=3421) was 0.008 (95% CI −0.003 to 0.020;
p=0.161; I2=74%; ﬁgure 5B).
Figure 1 Preferred reporting
items for systematic reviews and
meta-analyses flow of
randomised controlled trials.
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Table 1 Randomised trials characteristics
Study, year
Total
sample
size
Mean age
(linezolid/
vancomcyin) Type of infection
Intubation (%)
at baseline
(linezolid/
vancomycin)
Mean days of
therapy
(linezolid/
vancomycin)
Linezolid arm
(Gram-negative
coverage)
Vancomycin arm
(Gram-negative
coverage)
Primary
outcome
Jadad
score
Rubinstein
E (2001)20
396 63/61 Hospital-acquired
pneumonias
57.1/57.5 9.6/8.9 Linezolid
+aztreonam
Vancomycin
+aztreonam
CR and
ME at
TOC
4
Stevens DL
(2002)21
460 64/60 MRSA infections,
including
hospital-acquired
pneumonias
NR/NR 12.6/11.3 Linezolid
+aztreonam or
gentamicin
Vancomycin
+aztreonam or
gentamicin
CR and
ME at
TOC
3
Kaplan SL
(2003)22
316 2.2/2.9 Gram-positive
infections, including
hospital-acquired
pneumonias
NR/NR 11.3/12.2 Linezolid
+aztreonam or
gentamicin
Vancomycin
+aztreonam or
gentamicin
CR and
ME at
TOC
3
Wunderink
R (2003)23
623 63/62 Hospital-acquired
pneumonias
NR/NR 9.5/9.4 Linezolid
+aztreonam
Vancomycin
+aztreonam
CR and
ME at
TOC
3
Jaksic B
(2006)24
605 48/47 Neutropenic fever,
including
hospital-acquired
pneumonias
NR/NR 11.4/11.5 Linezolid
+Gram-negative
coverage
Vancomycin
+Gram-negative
coverage
CR and
ME at
TOC
4
Kohno S
(2007)25
151 68/67 MRSA infections,
including
hospital-acquired
pneumonias
NR/NR 10.9/10.6 Linezolid
+aztreonam or
gentamicin
Vancomycin
+aztreonam or
gentamicin
CR and
ME at
TOC
3
Wunderink
R (2008)26
149 56/55 MRSA
hospital-acquired
pneumonias
100/100 10.8/11.5 Linezolid
+Gram-negative
coverage
Vancomycin
+Gram-negative
coverage
CR and
ME at
FUV
3
Lin D
(2008)19
142 56.3/59.6 Gram-positive
infections, including
hospital-acquired
pneumonias
5.6/11.3 12.2/10.7 Linezolid
+aztreonam
Vancomycin
+aztreonam
CR at
FUV and
EOT
3
Wunderink
R (2012)10
1184 60.7/61.6 MRSA
hospital-acquired
pneumonias
60.5/66.5 10/10 Linezolid
+Gram-negative
coverage
Vancomycin
+Gram-negative
coverage
CR at
EOS
4
CON, control; CR, clinical response; EOT: end of therapy; EOS, end of study; FUV, follow-up visit; MRSA, methicillin resistant Staphylococcus aureus; ME, microbiological eradication; NR, not
reported; TRE, treatment; TOC, test of cure visit.
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Renal failure
The absolute RD between linezolid and vancomycin for
renal failure based on the intention-to-treat population
(N=3421) was −0.007 (95% CI −0.018 to 0.005; p=0.249;
I2=48%; ﬁgure 6A).
Drug discontinuation due to adverse events
The absolute RD between linezolid and vancomycin for
drug discontinuation based on the intention-to-treat
population (N=3421) was −0.005 (95% CI −0.016 to
0.007; p=0.424; I2=0%; ﬁgure 6B).
Figure 2 All-cause mortality.
Figure 3 (A) Clinical response—intention-to-treat population, (B) clinical response—per protocol population.
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SENSITIVITY ANALYSES
The trial by Jaksic et al24 was the only study that included
patients with leukaemia, active chemotherapy treatment
and several other nephrotoxic antibiotics such as
amphotericin and aminoclycosides; since these factors
can cause major gastrointestinal events (eg, graft vs host
disease, mucositis, Clostridium difﬁcile colitis), thrombo-
cytopenia (eg, disease-induced or drug-induced bone
marrow suppression) and renal failure (eg,
chemotherapy-induced or antibiotic-induced), this study
was not included in the prospectively planned side-effect
analyses. However, its inclusion to these analyses did not
change any of the original results. The trial by Kaplan
et al22 was the only one that included paediatric popula-
tion only; the removal of this study from all analyses did
not alter our results (data not shown); similarly the
removal of the oldest trial by Rubinstein et al also did
not change the results. The trials by Jaksic,24 Stevens,21
Lin,19 and Kohno25 included mortality for other sites of
infection; their removal did not change the overall
results. The trial by Wunderink et al10 was the only one
that did not provide 28-day mortality (only 60-day mor-
tality)—its removal from the mortality analysis did not
change the original ﬁndings (RD=0.006 (95% CI
−0.019 to 0.031); p=0.649; I2=21%). An analysis based
on the type of Gram-negative coverage produced similar
results. The analyses based on the quality of studies by
Jadad scores showed the following: 28-day mortality:
Jadad ≤3: RD=0.019 (95% CI −0.008 to 0.046); p=0.18;
I2=0%; Jadad >3: RD=−0.024 (95% CI −0.051 to 0.004);
p=0.10; I2=0%. Clinical response: Jadad ≤3: was 0.019
(95% CI −0.054 to 0.093); p=0.612; I2=0%; Jadad >3:
RD=0.04 (95% CI −0.058 to 0.138); p=0.426; I2=30%.
POWER CALCULATIONS
Mortality: Based on a prospectively planned expected
mortality rate at least 5% lower (95% CI −7% to −3%)
with linezolid, and a control mortality rate of 15%, the
sample size of our intention-to-treat meta-analysis
(N=2000 in each arm) has 99.9% power to detect a mor-
tality difference of 5% with a signiﬁcance level (α) of
0.05 (two-tailed).
Clinical response: Based on a prospectively planned
expected clinical response rate at least 10% higher (95%
CI 4% to 16%) with linezolid, and a control clinical
response of 57%, the sample size of our intention-
to-treat meta-analysis (N=2000 in each arm) has 99.9%
Figure 4 (A) Microbiological eradication—per protocol population, (B) Methicillin-resistant Staphylococcus aureus eradication—
per protocol population.
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power to detect a clinical response difference of 10%
with a signiﬁcance level (α) of 0.05 (two-tailed).
PUBLICATION BIAS ANALYSES
Mortality outcome: No publication bias was detected by
Egger regression (intercept=−0.038; SE=1.236; p=0.976),
or by Begg and Mazumdar rank correlation (Kendall’s
τ <0.0001; p=1.000).
Clinical response outcome: No publication bias was detected
by Egger regression (intercept=−0.790; SE=0.762;
p=0.334), or by Begg and Mazumdar rank correlation
(Kendall’s τ −0.027; p=0.917).
DISCUSSION
Our primary outcome analysis demonstrates that linezolid
and vancomycin are similar with respect to mortality reduc-
tion and clinical response. Our ﬁndings are robust and
clinically meaningful based on the high statistical power to
detect outcome differences between these two drugs—
100% power for both mortality and clinical response, and
the near zero heterogeneity for all efﬁcacy analyses.
Importantly, all analyses included only randomised
trials and accounted for the differences in study design,
which make the potential for selection and ascertain-
ment biases less likely. In addition, the clinical response
analyses showed no differences between both drugs in
the intention-to-treat as well as the per protocol patient
populations. Moreover, the clinical response in the per-
protocol patients with MRSA pneumonia likewise did
not show differences between drugs. Our secondary efﬁ-
cacy outcomes were also in agreement with our primary
outcomes; both microbiological eradication and MRSA
eradication were not different between vancomycin and
linezolid. Even though microbiological outcomes are
not necessarily as meaningful as survival and clinical
response, the absence of signiﬁcant microbiological out-
comes lends further support to the results of our
primary clinical and survival analysis.
Our efﬁcacy ﬁndings are also in agreement with two
previous meta-analyses8 9 that evaluated these antibiotics
to treat HAP, and two other meta-analyses27 28 that evalu-
ated these drugs and other antibiotics in patients with
multiple sites of infection, including pneumonias.
Figure 5 (A) Gastrointestinal events, (B) Thrombocytopenia.
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Consistency between the current meta-analysis and prior
analyses despite being performed by different research
groups using different statistical methods adds further
credence to our ﬁndings.
Our conclusions are contrary to those of Wunderink
et al10 whose recent clinical trial concluded that linezolid
has superior clinical efﬁcacy compared to vancomycin.
Closer examination of this trial, however, helps to recon-
cile their results with our meta-analysis. Of the 1184 par-
ticipants randomised into the Wunderink et al study,
only 339 (28%) were included in the clinical efﬁcacy
analysis. Excluding 72% of all randomised patients
undermined the balancing of potential confounders
conferred by randomisation. Not surprisingly, there were
notable differences between the linezolid and vanco-
mycin groups: patients treated with vancomycin had
higher rates of mechanical ventilation, bacteraemia, dia-
betes, renal failure and heart failure; and the levels of
vancomycin were suboptimal in half of the patients
enrolled in the trial biasing against clinical success with
vancomycin. The authors claimed linezolid superiority
based on their per protocol analysis but there was no sig-
niﬁcant difference in clinical response or mortality in
the intention-to-treat analysis. Of note, the CONSORT29
and ICH guidelines30 recommend intention-to-treat ana-
lyses for all clinical trials. Nonetheless, our meta-analysis
shows that even if one combines only the per-protocol
patients from all available trials comparing linezolid
versus vancomycin (ﬁgure 3B), the pooled results
including data from 1161 per-protocol patients still do
not show an advantage with linezolid. Last, it was stated
in the report by Wunderink et al10 that Pﬁzer had the
power to override the clinical outcomes as determined
by the investigators, but no details regarding the reasons
or extent of overriding were provided.
We found few differences in the drugs’ side effect pro-
ﬁles. The most signiﬁcant difference was found with
respect to gastrointestinal events, which were more fre-
quent with linezolid, while thrombocytopenia was
numerically, but not signiﬁcantly higher despite linezo-
lid’s well-known predilection to cause bone marrow sup-
pression. Differences in deﬁnitions of thrombocytopenia
used in the studies may have led to the high-observed
heterogeneity and may have precluded the detection of
this side effect with linezolid. The lack of difference
could, however, also be explained on clinical grounds:
Figure 6 (A) Renal failure, (B) study drug discontinuation due to adverse events.
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usual treatment courses for pneumonia may be too
short to realise the time-dependent risk of thrombocyto-
penia and vancomycin itself can also cause thrombocyto-
penia. Renal failure may be associated with vancomycin,
but it was not signiﬁcantly more frequent in patients
treated with vancomycin compared with linezolid in our
meta-analysis. Deﬁnitions of renal failure did vary
among studies, and may explain the high heterogeneity
for this analysis, but the very small difference in renal
failure rates (0.7%) among 3421 patients makes a signiﬁ-
cant difference unlikely. The lack of difference may also
reﬂect the more ‘healthy-patient’ inclusion biases of ran-
domised controlled trials. Finally, the comparable rates
of study drug discontinuation due to adverse events
(ﬁgure 6B) further afﬁrms a minimal difference in the
safety proﬁles between vancomycin and linezolid.
Limitations of our study follow from limitations in
the source trials. Randomised controlled trials set
selective inclusion criteria that can limit their generalis-
ability to unselected populations. None of the studies
speciﬁcally focused on MRSA with higher vancomycin
minimum-inhibitory concentrations nor did any of the
studies utilise continuous vancomycin infusion. Some
of the trials were open-label studies leading to potential
ascertainment bias for clinical endpoints; however, the
results of our analyses remained consistent when strati-
ﬁed by the presence or absence of blinding. The trad-
itional limitation of a lack of power to detect mortality
differences from individual trials on HAP is no longer a
concern as our meta-analysis included approximately
4000 patients and allowed close to 100% power to
detect a mortality or clinical response difference,
thereby conferring a high degree of conﬁdence that
there are no advantages for either drug. The hetero-
geneity was substantial for both gastrointestinal events
and thrombocytopenia; however, the lack of differences
and low heterogeneity seen within the study drug dis-
continuation due to adverse events analysis supports
our overall ﬁndings of a similar safety proﬁle between
drugs.
In conclusion, similar efﬁcacy and safety proﬁles show
that both vancomycin and linezolid are equivalent in
patients with HAP.
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